Vivani Medical Inc. Unveils Presentation on Innovative Obesity Treatment and Market Expansion Strategies

Reuters

2025/09/10

Vivani Medical Inc. Unveils Presentation on Innovative Obesity Treatment and Market Expansion Strategies

Vivani Medical Inc. recently held an investor presentation discussing its strategic approach to the evolving obesity market. The company highlighted the potential of a differentiated route of administration, offering a guaranteed-adherence option to improve patient outcomes and access untapped market segments. Currently, over 50 clinical-stage injectables or orals for obesity are in development, with Vivani's unique clinical-stage subdermal implant standing out as a distinctive option. The presentation emphasized the NanoPortal™ technology, which promises convenient and stable drug delivery, potentially reducing side effects and offering pricing flexibility. Vivani's clinical program is progressing, with the LIBERATE-1 study meeting its primary safety and device performance objectives. The GLP-1 market is projected to grow significantly, with Vivani poised to address unmet needs through its innovative product candidates. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivani Medical Inc. published the original content used to generate this news brief on September 09, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2566467256"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2566467256\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2566467256?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-10 06:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566467256","market":"fut","top_or_hot":-1,"title":"Vivani Medical Inc. Unveils Presentation on Innovative Obesity Treatment and Market Expansion Strategies","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Vivani Medical Inc. Unveils Presentation on Innovative Obesity Treatment and Market Expansion Strategies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Vivani Medical Inc. recently held an investor presentation discussing its strategic approach to the evolving obesity market. The company highlighted the potential of a differentiated route of administration, offering a guaranteed-adherence option to improve patient outcomes and access untapped market segments. Currently, over 50 clinical-stage injectables or orals for obesity are in development, with Vivani's unique clinical-stage subdermal implant standing out as a distinctive option. The presentation emphasized the NanoPortal™ technology, which promises convenient and stable drug delivery, potentially reducing side effects and offering pricing flexibility. Vivani's clinical program is progressing, with the LIBERATE-1 study meeting its primary safety and device performance objectives. The GLP-1 market is projected to grow significantly, with Vivani poised to address unmet needs through its innovative product candidates. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivani Medical Inc. published the original content used to generate this news brief on September 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vivani Medical Inc. Unveils Presentation on Innovative Obesity Treatment and Market Expansion Strategies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVivani Medical Inc. Unveils Presentation on Innovative Obesity Treatment and Market Expansion Strategies\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-10 06:03</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Vivani Medical Inc. Unveils Presentation on Innovative Obesity Treatment and Market Expansion Strategies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Vivani Medical Inc. recently held an investor presentation discussing its strategic approach to the evolving obesity market. The company highlighted the potential of a differentiated route of administration, offering a guaranteed-adherence option to improve patient outcomes and access untapped market segments. Currently, over 50 clinical-stage injectables or orals for obesity are in development, with Vivani's unique clinical-stage subdermal implant standing out as a distinctive option. The presentation emphasized the NanoPortal™ technology, which promises convenient and stable drug delivery, potentially reducing side effects and offering pricing flexibility. Vivani's clinical program is progressing, with the LIBERATE-1 study meeting its primary safety and device performance objectives. The GLP-1 market is projected to grow significantly, with Vivani poised to address unmet needs through its innovative product candidates. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivani Medical Inc. published the original content used to generate this news brief on September 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VANI","symbol_name":"Vivani Medical, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250909:nNDL5ywMLf:1","article_id":"2566467256","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566467256","pubTimestamp":1757455411,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Vivani Medical Inc. recently held an investor presentation discussing its strategic approach to the evolving obesity market. The company highlighted the potential of a differentiated route of administration, offering a guaranteed-adherence option to improve patient outcomes and access untapped market segments. Currently, over 50 clinical-stage injectables or orals for obesity are in development, with Vivani's unique clinical-stage subdermal implant standing out as a distinctive option. The presentation emphasized the NanoPortal technology, which promises convenient and stable drug delivery, potentially reducing side effects and offering pricing flexibility. Vivani's clinical program is progressing, with the LIBERATE-1 study meeting its primary safety and device performance objectives. The GLP-1 market is projected to grow significantly, with Vivani poised to address unmet needs through its innovative product candidates. You can access the full presentation through the link below.Discla","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VANI":"Vivani Medical, Inc.","BK4082":"医疗保健设备"},"translate_title":"Vivani Medical Inc.推出创新肥胖治疗和市场扩张策略演示","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VANI":0.9},"content_text":"Vivani Medical Inc. Unveils Presentation on Innovative Obesity Treatment and Market Expansion Strategies\n    \n\n        Vivani Medical Inc. recently held an investor presentation discussing its strategic approach to the evolving obesity market. The company highlighted the potential of a differentiated route of administration, offering a guaranteed-adherence option to improve patient outcomes and access untapped market segments. Currently, over 50 clinical-stage injectables or orals for obesity are in development, with Vivani's unique clinical-stage subdermal implant standing out as a distinctive option. The presentation emphasized the NanoPortal™ technology, which promises convenient and stable drug delivery, potentially reducing side effects and offering pricing flexibility. Vivani's clinical program is progressing, with the LIBERATE-1 study meeting its primary safety and device performance objectives. The GLP-1 market is projected to grow significantly, with Vivani poised to address unmet needs through its innovative product candidates. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivani Medical Inc. published the original content used to generate this news brief on September 09, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}